ChosenMed specializes in oncology precision medicine by providing early tumor screening and companion diagnostics through advanced genomic testing and artificial intelligence. The company addresses the critical need for early detection of asymptomatic cancers, enabling targeted prevention and treatment for high-risk patients.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of asymptomatic cancers is critical for effective prevention and treatment, yet current screening methods often lack the sensitivity and specificity needed to identify high-risk individuals. Traditional tumor screening methods may also be invasive or unsuitable for frequent monitoring.
Solution
ChosenMed leverages advanced genomic testing and artificial intelligence to provide early tumor screening and companion diagnostics in oncology. Their approach focuses on identifying cancer at its earliest stages, even before symptoms appear, enabling targeted interventions and personalized treatment plans. By analyzing a patient's unique genomic profile, ChosenMed aims to improve the accuracy and efficiency of cancer detection, leading to better outcomes for high-risk individuals. The company also contributes to drug development by discovering biomarkers specific to the Chinese population.
Target Audience
The primary target audience includes individuals at high risk for cancer, medical professionals in oncology, and pharmaceutical companies involved in anti-tumor drug development.
Features
- ChosenHawKEye: Early screening test for digestive tract tumors.
- ChosenEarly: Early screening test for liver cancer.
- Comprehensive tumor gene detection products covering solid tumors and hematological malignancies.
- ChosenReportInfo: Automated intelligent reporting system for streamlined analysis.
- ChosenAuto: Automated sequencing laboratory system for high-throughput processing.
- Participation in the China Tumor Genome Atlas Project to identify unique biomarkers.
- AI-driven analysis of genomic data for improved diagnostic accuracy.